Durability of Response

Durability of response measures treatment benefit persistence beyond initial efficacy assessment. Disease progression after initial response indicates acquired resistance. Continued response maintenance throughout extended follow-up demonstrates durable benefit. Relapse patterns characterise disease recurrence risk. Time-to-progression analysis quantitates durability across patient populations.

Progression-free survival represents standard efficacy endpoint measuring durability. Overall survival provides definitive but delayed durability assessment. Biomarker monitoring detects early progression enabling intervention. Combination therapies targeting multiple resistance pathways improve durability. Regulatory submissions emphasise durable efficacy benefiting patients most.